We shape the future of the Greek and European pharmaceutical industry through international presence, investments in research and strategic development.
With over 1,700 employees, together we create a culture of progress, innovation and contribution.
Through the Athens LifeTech Park, the first biotechnology park in Southeastern Europe, we invest in cutting-edge infrastructure, R&D and new partnerships, bringing science closer to the patient.
To be a benchmark in pharmaceutical innovation, based on a human-centered approach.
Exports to 90 countries, subsidiaries in Germany and the UAE, strategic partnerships on a global scale.
From production to social contribution, ΕLPEN supports sustainable practices and actions of measurable social impact.
Continuous training, equal opportunities and substantial care for those who build the future of ELPEN.
A story of research, development and dedication to human life.
years of operation in the Greek pharmaceutical industry
employees with continuous professional development
countries presence worldwide
proprietary preparations in 13 therapeutic categories
patients in Greece and abroad use ELPEN medicines
At ELPEN, the following have been implemented: